Vanguard Group
VRDN icon

Vanguard Group’s Viridian Therapeutics VRDN Stock Holding History

Vanguard Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$175M Buy
5,612,144
+1,280,161
+30% +$35.1M ﹤0.01% 1615
2025
Q3 		$93.5M Sell
4,331,983
-176,525
-4% -$3.18M ﹤0.01% 1883
2025
Q2 		$63M Sell
4,508,508
-54,592
-1% -$741K ﹤0.01% 2025
2025
Q1 		$61.5M Sell
4,563,100
-31,949
-0.7% -$544K ﹤0.01% 2007
2024
Q4 		$88.1M Buy
4,595,049
+174,952
+4% +$3.8M ﹤0.01% 1928
2024
Q3 		$101M Buy
4,420,097
+1,074,366
+32% +$17.6M ﹤0.01% 1871
2024
Q2 		$43.5M Buy
3,345,731
+111,452
+3% +$1.54M ﹤0.01% 2204
2024
Q1 		$56.6M Buy
3,234,279
+233,331
+8% +$4.52M ﹤0.01% 2114
2023
Q4 		$65.4M Buy
3,000,948
+552,933
+23% +$8.73M ﹤0.01% 2076
2023
Q3 		$37.6M Sell
2,448,015
-148,629
-6% -$2.84M ﹤0.01% 2264
2023
Q2 		$61.8M Buy
2,596,644
+466,411
+22% +$12M ﹤0.01% 2092
2023
Q1 		$54.2M Buy
2,130,233
+15,239
+0.7% +$489K ﹤0.01% 2138
2022
Q4 		$61.8M Buy
2,114,994
+258,194
+14% +$5.95M ﹤0.01% 2068
2022
Q3 		$38.1M Buy
1,856,800
+445,898
+32% +$8.02M ﹤0.01% 2309
2022
Q2 		$16.3M Buy
1,410,902
+470,325
+50% +$6.32M ﹤0.01% 2743
2022
Q1 		$17.4M Buy
940,577
+14,901
+2% +$286K ﹤0.01% 2850
2021
Q4 		$18.3M Buy
925,676
+463,764
+100% +$8.64M ﹤0.01% 2887
2021
Q3 		$7.6M Buy
461,912
+107,846
+30% +$1.58M ﹤0.01% 3404
2021
Q2 		$6.48M Buy
354,066
+185,548
+110% +$3.18M ﹤0.01% 3449
2021
Q1 		$2.81M Buy
168,518
+8,430
+5% +$158K ﹤0.01% 3782
2020
Q4 		$2.63M Buy
160,088
+54,633
+52% +$824K ﹤0.01% 3591
2020
Q3 		$1.23M Sell
105,455
-173
-0.2% -$2.58K ﹤0.01% 3612
2020
Q2 		$1.76M Sell
105,628
-1,755
-2% -$19.9K ﹤0.01% 3465
2020
Q1 		$718K Buy
107,383
+63,960
+147% +$744K ﹤0.01% 3585
2019
Q4 		$312K Hold
43,423
– – ﹤0.01% 3876
2019
Q3 		$477K Buy
43,423
+2,229
+5% +$49.3K ﹤0.01% 3830
2019
Q2 		$1.27M Buy
41,194
+11,272
+38% +$453K ﹤0.01% 3602
2019
Q1 		$1.25M Buy
29,922
+1,329
+5% +$60.1K ﹤0.01% 3569
2018
Q4 		$1.3M Sell
28,593
-28,963
-50% -$1.68M ﹤0.01% 3489
2018
Q3 		$4.82M Sell
57,556
-595
-1% -$56.1K ﹤0.01% 3253
2018
Q2 		$5.59M Buy
58,151
+3,751
+7% +$397K ﹤0.01% 3176
2018
Q1 		$5.72M Buy
54,400
+27,226
+100% +$2.96M ﹤0.01% 3083
2017
Q4 		$4.25M Buy
27,174
+24,276
+838% +$3.09M ﹤0.01% 3193
2017
Q3 		$398K Buy
2,898
+152
+6% +$25.6K ﹤0.01% 3793
2017
Q2 		$532K Buy
2,746
+2,050
+295% +$346K ﹤0.01% 3715
2017
Q1 		$130K Hold
696
– – ﹤0.01% 3966
2016
Q4 		$53K Buy
696
+240
+53% +$25.1K ﹤0.01% 4026
2016
Q3 		$50K Hold
456
– – ﹤0.01% 4033
2016
Q2 		$44K Sell
456
-149
-25% -$18.3K ﹤0.01% 4088
2016
Q1 		$69K Sell
605
-163
-21% -$20.8K ﹤0.01% 4055
2015
Q4 		$130K Hold
768
– – ﹤0.01% 4058
2015
Q3 		$160K Buy
768
+291
+61% +$102K ﹤0.01% 4052
2015
Q2 		$235K Buy
477
+134
+39% +$54.3K ﹤0.01% 4019
2015
Q1 		$166K Buy
+343
New +$198K ﹤0.01% 4022

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group's VRDN Position: Q4 2025 in Review

Vanguard Group increased its Viridian Therapeutics (VRDN) stake by 30% in Q4 2025, buying an estimated $35.1M and bringing the position to 5,612,144 shares worth $175M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Vanguard Group first reported a position in VRDN in Q1 2015 and has held it in 44 quarters since. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Vanguard Group held 5,612,144 shares of Viridian Therapeutics worth $175M as of Q4 2025.
  • Vanguard Group bought 1,280,161 Viridian Therapeutics shares in Q4 2025, an estimated $35.1M.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1615 holding.
  • Vanguard Group first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 44 quarters since.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.